1164
Gd-EMF-IL-13 and 177lu-EMF-IL-13 Endohedral Metallofullerene: A Targeting Diagnostic and Therapeutic Platform for Glioblastoma Multiforme Brain Tumors

Monday, May 12, 2014: 09:20
Bonnet Creek Ballroom X, Lobby Level (Hilton Orlando Bonnet Creek)
B. Kiselev (Virginia Tech Carilion School of Medicine), J. Zhang (Virginia Tech Carilion Research Institute, Virginia Polytechnic Institute & State University), S. Murphy, T. Li, Z. Sheng (Virginia Tech Carilion Research Institute), and H. C. Dorn (Virginia Tech Carilion Research Institute, Virginia Polytechnic Institute & State University)
Glioblastoma multiforme (GBM) brain tumors represent a devastating disease with no really effective treatment.  GBM carries a life expectancy from the time of diagnosis of about 14 months. In this paper we report results for a novel carbonaceous platform, namely, endohedral metallofullerenes (Gd-EMF-IL-13 and 177Lu-EMF-IL-13), as a new multi-modal “theranostic” platform for the diagnosis and treatment of infiltrative GBM tumors. The targeting modality is a cytokine, interleukin-13 (IL-13), which is over-expressed in human and animal GBM cell lines, and is a key addition to the nanoparticle platform that has not been previously employed in therapeutic EMF studies. Our recent results for preparing and in vivo results for multi-modal endohedral metallofullerenes will be the focus of this presentation.1

References:

 1. Zhang, J.; Stevenson, S.; Dorn, H.C. Trimetallic Nitride Endohedral Metallofullerenes: Discovery, Structural Characterization, Reactivity, and Applications.  Accounts of Chemical Research, 2013, 46(7), 1548-1557

See more of: Carbon Nanostructures in Medicine and Biology I
See more of: M3: Carbon Nanostructures in Medicine and Biology
See more of: Carbon Nanostructures and Devices
<< Previous Abstract | Next Abstract